Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 294
- Registration Number
- NCT02549677
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
- Conditions
- Interventions
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2015-07-29
- Target Recruit Count
- 200
- Registration Number
- NCT02510781
- Locations
- 🇨🇳
Hospital affiliated to military medical science, Beijing, Beijing, China
Adjuvant FEC Versus EP in Breast Cancer (MIG5)
- Conditions
- Interventions
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2015-05-21
- Target Recruit Count
- 1055
- Registration Number
- NCT02450058
- Locations
- 🇮🇹
Federico Castiglione, Alba, Italy
🇮🇹Ornella Garrone, Cuneo, Italy
🇮🇹Lucia Del Mastro, Genoa, Italy
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 125
- Registration Number
- NCT02400567
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷Institut Curie, Paris, France
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 438
- Registration Number
- NCT02395640
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 297
- Registration Number
- NCT02338518
- Locations
- 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 174
- Registration Number
- NCT02324088
Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Centro di Riferimento Oncologico - Aviano
- Target Recruit Count
- 46
- Registration Number
- NCT02307227
- Locations
- 🇮🇹
Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 75
- Registration Number
- NCT02287129
- Locations
- 🇩🇪
2nd department of the Medical Clinic of the Technical University Munich, Munich, Bavaria, Germany
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 240
- Registration Number
- NCT02214602
- Locations
- 🇪🇬
Urology and Nephrology Center, Mansoura, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.